Hypertension Journal

NOVEMBER 29, 2023

Hypertension, Ahead of Print. Hypertension-associated cerebral small vessel disease is a common finding in older people. Strongly associated with age and hypertension, small vessel disease is found at autopsy in over 50% of people aged ≥65 years, with a spectrum of clinical manifestations.

Dementia 64

Dementia Hypertension Pharmacology Biomarkers 64

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Background Hypertension has now developed into a major public health problem worldwide. Acupuncture, a core technique in the non-pharmacological treatment of Chinese medicine, plays an important role in the treatment of elevated blood pressure. to −6.06, P  < 0.01) and DBP (MD: −7.04, 95% CI: −10.83 to −3.24, P  < 0.01).

Hypertension 64

Hypertension Blood Pressure Public Health Pharmacology 64

Hypertension Journal

JANUARY 2, 2024

Hypertension, Ahead of Print. Pharmacological inhibition of EGFR or downstream ER stress may be a promising therapeutic strategy for preventing aneurysm rupture and subarachnoid hemorrhage. BACKGROUND:Multiple pathways and factors are involved in the rupture of intracranial aneurysms.

Aneurysm 45

Aneurysm Pharmacology Atherosclerosis Hemorrhage 45

Hypertension Journal

NOVEMBER 6, 2024

Hypertension, Volume 82, Issue 1 , Page 72-83, January 1, 2025. BACKGROUND:Hypertension increases the risk of lymphedema in patients with comorbidities, but whether hypertension directly compromises lymph vessel (LV) function and lymph flow is unclear. fold lower in Ang II-induced hypertensive rats compared with normotensive rats.

Hypertension 40

Hypertension Pharmacology 40

Frontiers in Cardiovascular Medicine

MAY 22, 2024

IntroductionPulmonary hypertension (PH) is a pathological condition that affects approximately 1% of the population. Lastly, we analyzed the mechanisms of action of several existing and novel pharmacological treatments for PH. The prognosis for many patients is poor, even after treatment. Then, we associated SRC with IL6 signaling.

Hypertension 52

Hypertension Pulmonary Pharmacology 52

Circulation

FEBRUARY 5, 2024

BACKGROUND:Pulmonary hypertension (PH) is a progressive cardiopulmonary disease with a high mortality rate. Our findings also suggest that ME1 may represent as a novel pharmacological target for upregulating protective adenosine signaling in PH therapy. Circulation, Ahead of Print.

Pulmonary 45

Pulmonary Hypertension Pharmacology Circulation 45

Stroke: Vascular and Interventional Neurology

DECEMBER 8, 2024

Here we aimed to assess the association between pharmacologic inhibition of angiotensinconverting enzyme and subsequent nontraumatic SAH.METHODSIn a retrospective cohort study based on Optum's Clinformatics Datamart deidentified database records (20002021), we included all subjects with a history of hypertension. million, followup: 6.3

Hypertension 40

Hypertension Hemorrhage Pharmacology Aneurysm 40

Stroke Journal

JANUARY 30, 2025

Here we aimed to assess the association between pharmacologic inhibition of angiotensin-converting enzyme and subsequent non-traumatic SAHMethods:In a retrospective cohort study based on Optums Clinformatics Datamart de-identified Database records (2000-2021), patients with hypertension were included. million,follow-up:6.3

Hemorrhage 40

Hemorrhage Hypertension Aneurysm Pharmacology 40

Circulation

NOVEMBER 11, 2024

Background:Primary pulmonary arterial hypertension (PAH) is a disease affecting young subjects. Pharmacological inhibition of GPR39 may open new frontiers in the treatment of PAH. Circulation, Volume 150, Issue Suppl_1 , Page A4117657-A4117657, November 12, 2024. It has very poor prognosis and optimal treatment is not available.

Pulmonary 40

Pulmonary Hypertension Blood Pressure Pharmacology 40

Journal of Cardiovascular Pharmacology

FEBRUARY 3, 2025

Hypertension is a major risk factor for cardiovascular disease (CVD), and a major contributor to global morbidity and mortality. Aprocitentan has been recently FDA-approved, marking a major milestone in hypertension management, offering hope for patients with difficult-to-treat hypertension. All rights reserved.

Hypertension 40

Hypertension Blood Pressure Risk Factors Cardiovascular Disease 40

Journal of Cardiovascular Pharmacology

JUNE 24, 2024

Management is particularly challenging in patients with uncontrolled hypertension. The treatment aims to improve postural symptoms while minimising side effects and reducing iatrogenic exacerbation of supine hypertension. Management is particularly challenging in patients with uncontrolled hypertension.

Pharmacology 40

Pharmacology Hypertension Education Article 40

International Journal of Cardiovascular Sciences

MARCH 13, 2023

These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome. Numerous pharmacological and non-pharmacological interventions have been developed to control and improve clinical outcomes, and all these aspects involve cardiometabolic diseases.

Pharmacology 52

Pharmacology Article Obesity Risk Factors 52

Journal of Cardiovascular Pharmacology

OCTOBER 14, 2024

Lisinopril is commonly prescribed to manage conditions such as hypertension and heart failure. Lisinopril is commonly prescribed to manage conditions such as hypertension and heart failure.

Pharmacology 40

Pharmacology Heart Failure Hypertension Research 40

Journal of Cardiovascular Pharmacology

NOVEMBER 7, 2024

However, the renal effects of different doses of liraglutide in an essential hypertension model have not yet been investigated. liraglutide appears to have distinct effects on the hypertensive female kidney depending on the dose, with higher doses impairing kidney function. mg/kg, LL) and high (0.6 mg/kg, LH) doses.

Hypertension 40

Hypertension Blood Pressure Article 40

Heart BMJ

OCTOBER 10, 2024

The review introduces a mediation model, delineating the intricate interplay between hypertension and diabetes and their joint contribution to cardiovascular and renal pathologies. Finally, we outline the role of lifestyle changes and other pharmacological options in attenuating cardiometabolic risks in patients with type 2 diabetes.

Blood Pressure 52

Blood Pressure Diabetes Pharmacology Cardiovascular Disease 52

Nature Reviews - Cardiology

FEBRUARY 6, 2025

Nature Reviews Cardiology, Published online: 07 February 2025; doi:10.1038/s41569-025-01131-4 Hypertension is the leading cause of death globally but has low rates of diagnosis and treatment.

Blood Pressure 135

Blood Pressure Pharmacology Hypertension 135

Frontiers in Cardiovascular Medicine

JULY 1, 2024

IntroductionThe incidence of metabolic disorders during pregnancy is increasing year by year, with diseases including hypertension and hyperlipidemia. Statins are the primary drugs for treating hyperlipidemia or atherosclerosis, yet some patients remain unresponsive to them, and pregnant women are prohibited from taking statins.

Cholesterol 52

Cholesterol Pharmacology Atherosclerosis Cancer 52

Journal of Cardiovascular Pharmacology

FEBRUARY 26, 2024

Our objective is to examine the risk of hypertension in patients with autoimmune diseases undergoing IL-17 inhibition therapies via meta-analysis of randomized, placebo-controlled trials (RCTs). Among the four agents (secukinumab, ixekizumab, bimekizumab, and brodalumab), only secukinumab exhibited a notable association with hypertension.

Hypertension 40

Hypertension Blood Pressure Article 40

Journal of Cardiovascular Pharmacology

JUNE 27, 2012

The aim was to explore the effect of irbesartan combining with emodin on myocardial remodeling in goldblatt (2K-1C) hypertensive rats. Conclusions: Irbesartan or Emodin or two drugs together can inhibit myocardial remodeling in renovascular hypertension rats probably by reducing TGF-β1 and CTGF expression. Correspondence to: Prof.

Hypertension 40

Hypertension Blood Pressure Document Cardiovascular Disease 40

HeartRhythm

SEPTEMBER 4, 2024

This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Quality of Life 40

Journal of Cardiovascular Pharmacology

MARCH 13, 2024

Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, imposing overload on the right ventricle (RV) and imbalance of redox state. Male Wistar rats were separated into four groups: control (CTR); control + sulforaphane (CTR + SFN); monocrotaline (MCT); monocrotaline + sulforaphane (MCT + SFN).

Pulmonary 40

Pulmonary Hypertension Tricuspid Cardiac Function 40

Journal of Cardiovascular Pharmacology

JULY 1, 2024

However, whether AMOTL2 is linked to pulmonary arterial hypertension (PAH) has not been addressed. However, whether AMOTL2 is linked to pulmonary arterial hypertension (PAH) has not been addressed. Abstract: Angiomotin-like 2 (AMOTL2) is related to numerous physiological and pathological conditions by affecting signal transduction.

Pulmonary 40

Pulmonary Hypertension Physiology Article 40

Hypertension Journal

AUGUST 22, 2024

Hypertension, Ahead of Print. BACKGROUND:Although the concept of the intrarenal renin-angiotensin system (RAS) in renal disease is well-described in the literature, the precise pathogenic role and mechanism of this local system have not been directly assessed in the absence of confounding influence from the systemic RAS.

Pharmacology 40

Pharmacology Hypertension 40

Hypertension Journal

MARCH 6, 2025

Hypertension, Ahead of Print. Both siRNA-mediatedACLYknockdown and pharmacological ACLY inhibition suppressed the proliferation and expression of fibrous proteins in cultured human cardiac fibroblasts stimulated with transforming growth factor-.

Pharmacology 45

Pharmacology Heart Failure Hypertension 45

Journal of Cardiovascular Pharmacology

NOVEMBER 11, 2024

Pulmonary arterial hypertension (PAH) is a cardiopulmonary vascular condition with an unclear pathogenesis. Pulmonary arterial hypertension (PAH) is a cardiopulmonary vascular condition with an unclear pathogenesis. Microarray data for PAH and ER stress-related genes were analyzed.

Pulmonary 40

Pulmonary Hypertension Article 40

Journal of the American Heart Association

DECEMBER 29, 2023

Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. However, studies on how obesity affects pharmacologic or interventional AF treatments are limited. AF increases the risk of stroke, heart failure, dementia, and hospitalization.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Pharmacology 45

Journal of the American Heart Association

FEBRUARY 26, 2025

BackgroundAbdominal aortic aneurysm (AAA) is a severe aortic disease for which no pharmacological interventions have yet been developed. Journal of the American Heart Association, Ahead of Print. Colocalization analysis pinpointed 13 proteins with strong evidence of colocalization with AAA.

Aneurysm 40

Aneurysm Risk Factors Aortic Obesity 40

Heart BMJ

MAY 10, 2024

1 While much effort has been directed at pharmacological and interventional techniques to improve outcomes for those living with these conditions, less has been directed towards identifying factors associated with increased incident risk of AF and non-AF arrhythmias, and strategies to ameliorate them.

Arrhythmia 40

Arrhythmia Myocardial Infarction Atrial Fibrillation Heart Failure 40

Stroke Journal

DECEMBER 21, 2023

PRES etiologies are usually dichotomized into toxic PRES (eg, antineoplastic drugs, illicit drugs) and clinical condition-associated PRES (eg, acute hypertension, dysimmune disorders). Research into the pathogenesis of PRES has emerged through the development of animal models in the last decade.

Hypertension 40

Hypertension Pharmacology Diet Research 40

Journal of Cardiovascular Pharmacology

JANUARY 16, 2024

Pulmonary arterial hypertension (PAH) is a persistent condition affecting the pulmonary arteries' endothelium. The present study was designed to investigate the effect of benidipine alone and in combination with bosentan and sildenafil on monocrotaline (MCT)-induced pulmonary hypertension (PH) in a rat model.

Pulmonary 40

Pulmonary Hypertension Article 40

Hypertension Journal

FEBRUARY 6, 2024

Hypertension, Ahead of Print. With limited pharmacological therapeutic strategies that target the structural changes in the aorta, surgical intervention remains the only option for some patients with these diseases.

Aortic 40

Aortic Atherosclerosis Pharmacology Aneurysm 40

Stroke Journal

JANUARY 30, 2025

Contributing factors such as hypocholesterolemia and hypertension amplify the risk of ICH and subsequent hematoma expansion, underscoring the urgent need for effective interventions.

Hemorrhage 40

Hemorrhage Pharmacology Hypertension Outcomes 40

Hypertension Journal

FEBRUARY 16, 2024

Hypertension, Ahead of Print. Pharmacological inhibition of T-type channels alone will likely not significantly impact aldosterone production in the long term. BACKGROUND:The zona glomerulosa of the adrenal gland is responsible for the synthesis and release of the mineralocorticoid aldosterone.

Blood Pressure 45

Blood Pressure Pharmacology Hypertension 45

ADN Center of Excellence

SEPTEMBER 2, 2024

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59

AFIB Atrial Fibrillation Innovation Heart Rhythm 59

Dr. Smith's ECG Blog

FEBRUARY 8, 2015

Dilated pupils and hypertension are a strong clue to sympathetic overload, but don't forget anticholinergic syndromes, including tricyclics! I have treated several patients with severe hypertension and tachycardia due to cocaine and/or methamphetamine with a combination of esmolol + nitroprusside or phentolamine.

Tachycardia 52

Tachycardia Chest Pain Pharmacology Myocardial Infarction 52

Journal of Cardiovascular Pharmacology

APRIL 4, 2024

Myocardial infarction (MI) and pulmonary artery hypertension (PAH) are two prevalent cardiovascular diseases. Myocardial infarction (MI) and pulmonary artery hypertension (PAH) are two prevalent cardiovascular diseases. In both conditions, oxidative stress is associated with a worse prognosis.

Myocardial Infarction 40

Myocardial Infarction Cardiovascular Disease Pulmonary Hypertension 40

Journal of Cardiovascular Pharmacology

DECEMBER 25, 2023

Shortness of breath and syncope are common symptoms of right ventricular failure caused by pulmonary arterial hypertension (PAH), which is the result of blockage and increased pressure in the pulmonary arteries. Therefore, our research showed that RA protects against MCT-induced PAH by reducing inflammation and vascular calcification in rats.

Pulmonary 40

Pulmonary Hypertension Research Article 40